← Back to Search

Insulin Injection Sites for Diabetes

N/A

Waitlist Available

Led By Graydon Meneilly, MD

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

At least 19 years of age

Diagnosed with Type 1 or Type 2 diabetes for at least 2 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up continuously for 12 days

Awards & highlights

Study Summary

This trialexamines if injecting insulin in areas of subclinical lipohypertrophy affects insulin absorption and glycemic control in people with diabetes.

Who is the study for?

This trial is for people over 19 who have had Type 1 or Type 2 diabetes for at least two years and are using insulin. They must have been part of phase 1 of the study and identified with subclinical lipohypertrophy. Those on certain diabetes medications, steroids, or unable to communicate in English without a translator cannot join.Check my eligibility

What is being tested?

The study is looking into how well insulin is absorbed in areas affected by subclinical lipohypertrophy—a kind of localized swelling due to repeated injections. At least 20 participants will use continuous glucose monitoring to see if there's a link between their blood sugar control and the amount of insulin injected into these swollen spots.See study design

What are the potential side effects?

Since this trial involves standard diabetes care practices, side effects may include those typically associated with insulin therapy such as low blood sugar levels, injection site reactions, and possible skin changes where injections are given.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 19 years old or older.

Select...

I have been diagnosed with diabetes for at least 2 years.

Select...

I use insulin to manage my diabetes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ continuously for 12 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~continuously for 12 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and continuously for 12 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Blood glucose levels

Trial Design

2Treatment groups

Experimental Treatment

Group I: Normal Subcutaneous TissueExperimental Treatment1 Intervention

Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.

Group II: LipohypertrophyExperimental Treatment1 Intervention

Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,413 Previous Clinical Trials

2,466,952 Total Patients Enrolled

10 Trials studying Diabetes

363 Patients Enrolled for Diabetes

MedtronicIndustry Sponsor

605 Previous Clinical Trials

828,186 Total Patients Enrolled

4 Trials studying Diabetes

164 Patients Enrolled for Diabetes

Graydon Meneilly, MDPrincipal InvestigatorUniversity of British Columbia

6 Previous Clinical Trials

165 Total Patients Enrolled

1 Trials studying Diabetes

100 Patients Enrolled for Diabetes

Media Library

Lipohypertrophy Clinical Trial Eligibility Overview. Trial Name: NCT02748434 — N/A

Diabetes Research Study Groups: Lipohypertrophy, Normal Subcutaneous Tissue

Diabetes Clinical Trial 2023: Lipohypertrophy Highlights & Side Effects. Trial Name: NCT02748434 — N/A

Lipohypertrophy 2023 Treatment Timeline for Medical Study. Trial Name: NCT02748434 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment for the trial still open at this time?

"The current data hosted on clinicaltrials.gov suggests that this trial, which was first posted in October 2016 and last modified at the end of 2022, is no longer recruiting participants. Fortunately, there are still 1259 other trials searching for volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Glucose Variability in Subclinical Hypertrophy

Graydon Meneilly 2016. "Glucose Variability in Subclinical Hypertrophy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02748434.

All > Hypertrophy